Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Research Initiative
Collaboration to Accelerate Breakthroughs in the
Treatment and Prevention of Cancer, Infectious and Autoimmune Diseases
IVRI is designed to explore the unique synergy between cancer and infectious disease research and to accelerate breakthrough discoveries in both areas. IVRI researchers are working closely with collaborators and sponsors with the shared goal of discovering and advancing immunotherapeutics and vaccine strategies.
“In the last several years, we have learned so much about the role of the immune system in treating disease, and we look forward to harnessing that information across both research and industry to develop innovative new treatment options to improve patient care,” said
“Through this unique collaboration, there is tremendous opportunity to improve our understanding of the immune system’s potential to serve as an important weapon in treating cancer and infectious disease,” said
The IVRI officially launched with a reception on
About Immunotherapeutics and Vaccine Research Initiative (IVRI)
The immune system is nature’s most powerful weapon against disease. Whether introduced to the host from the environment, arising endogenously or stemming from a dysfunction of the immune system itself, diseases are impacted by immune functions, and the immune response can be targeted for therapy. It is our vision that a fundamental understanding of immune recognition, cellular interactions and other elements of the immune system has high potential to lead to meaningful advancements in the treatment of many diseases.
The IVRI is envisioned as a center for research to develop mechanistic understanding and application of immunology, pathogenesis and vaccinology with the potential to profoundly impact the treatment of human disease. The initiative is founded on the principle that research that uncovers how the immune system controls infectious disease yields new approaches for treating cancer, and conversely, that studies of cancer immunology yield approaches for vaccines and therapies targeting infectious disease. UC Berkeley has an impressive record in this endeavor including advances that have led to cancer immunotherapeutics and novel vaccines. The IVRI will expand on and accelerate these advances by coordinating and directing the efforts of UC Berkeley researchers, their collaborators and sponsors towards ground-breaking discoveries, and the development of creative new applications in disease prophylaxis and treatment. The IVRI will facilitate communication and collaboration among researchers, streamline access to scientific and financial resources and promote not only the vision, ideas and accomplishments of its scientists, but also the translation of these ideas and findings for the development of new therapies for human diseases. By targeting synergies in the expertise and capabilities of its scientists and unifying their ingenuity with the objectives of its sponsors, the IVRI seeks to maximize the potential of its UC Berkeley researchers and accelerate the pace of discovery and translation.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential of IVRI to yield new therapies, the potential for our technology, plans and timing of our clinical trials and the potential for eventual regulatory approval of our product candidates. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our annual report on Form 10-K for the year ended
Sylvia WheelerSVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting925 202 6211 email@example.com Mike Beyer Sam Brown, Inc.312 961 2502